BEVQOLVA DIN 02567865
Health Canada record
| Active ingredient(s) | BEVACIZUMAB 400 MG |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | SCHEDULE D; PRESCRIPTION |
| Class | Human |
| ATC | L01FG01 BEVACIZUMAB |
| Original market date | |
| Current status date | 28-Apr-2026 |
| Source | Health Canada DPD |
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing BEVACIZUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02522160 | ABEVMY | BIOCON BIOLOGICS CANADA INC | Solution | BEVACIZUMAB 400 MG | Marketed |
| 02522179 | ABEVMY | BIOCON BIOLOGICS CANADA INC | Solution | BEVACIZUMAB 100 MG | Marketed |
| 02270994 | AVASTIN | HOFFMANN-LA ROCHE LIMITED | Solution | BEVACIZUMAB 25 MG | Marketed |
| 02522837 | AYBINTIO | SAMSUNG BIOEPIS CO., LTD | Solution | BEVACIZUMAB 400 MG | Marketed |
| 02522829 | AYBINTIO | SAMSUNG BIOEPIS CO., LTD | Solution | BEVACIZUMAB 100 MG | Marketed |
| 02520729 | BAMBEVI | APOTEX INC | Solution | BEVACIZUMAB 100 MG | Marketed |
| 02520737 | BAMBEVI | APOTEX INC | Solution | BEVACIZUMAB 400 MG | Marketed |
| 02567830 | BEVQOLVA | CURATEQ BIOLOGICS PRIVATE LIMITED | Solution | BEVACIZUMAB 100 MG | Approved |
| 02470748 | MVASI | AMGEN CANADA INC | Solution | BEVACIZUMAB 25 MG | Marketed |
| 02470756 | MVASI | AMGEN CANADA INC | Solution | BEVACIZUMAB 25 MG | Marketed |
| 02534177 | VEGZELMA | CELLTRION INC. | Solution | BEVACIZUMAB 100 MG | Marketed |
| 02534185 | VEGZELMA | CELLTRION INC. | Solution | BEVACIZUMAB 400 MG | Marketed |
| 02489430 | ZIRABEV | PFIZER CANADA ULC | Solution | BEVACIZUMAB 100 MG | Marketed |
| 02489449 | ZIRABEV | PFIZER CANADA ULC | Solution | BEVACIZUMAB 400 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 37450 | 2026-04-28 | New Drug Submission (NDS) |